Neuropathic Pain Treatment Market
Neuropathic Pain Treatment Market Size, Share & Trends Analysis Report, By Drug Class (Antidepressants, Anticonvulsants, Opioids, Topical Agents, Others), By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment), By Indication (Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Chemotherapy-Induced Peripheral Neuropathy, Trigeminal Neuralgia, Spinal Cord Injury Pain, Others), Forecast Period (2026-2035)
Industry Overview
Neuropathic pain treatment market size was valued at $10.9 billion in 2025 and is projected to reach $19.2 billion by 2035, expanding at a CAGR of 5.8% during 2026–2035. Neuropathic pain, caused by nerve damage or dysfunction, represents a significant global healthcare burden, particularly among aging populations and individuals with chronic conditions such as diabetes and cancer. According to the International Association for the Study of Pain (IASP), chronic pain affects nearly 20% of adults globally, with neuropathic pain constituting a substantial proportion. Additionally, the International Diabetes Federation (IDF) estimates that over 537 million adults were living with diabetes in 2023, increasing the prevalence of diabetic neuropathy.
The market is primarily driven by rising demand for pharmacological treatments, including anticonvulsants and antidepressants, alongside increasing adoption of neuromodulation devices. Growth is further supported by advancements in precision medicine, biologics, and minimally invasive therapies.
Market Dynamics
Rising Prevalence of Chronic Diseases Driving Market Growth
The increasing prevalence of chronic diseases such as diabetes, cancer, and neurological disorders is a key driver of the Neuropathic Pain Treatment Market growth. According to the International Diabetes Federation (IDF), global diabetes prevalence is expected to reach 643 million by 2030, significantly increasing the incidence of diabetic peripheral neuropathy. Furthermore, the World Health Organization (WHO) reports that cancer cases are expected to rise to 29.5 million by 2040, contributing to chemotherapy-induced neuropathic pain cases. These trends directly boost demand for effective pain management solutions.
Pharmaceutical companies are actively investing in drug innovation and expanded indications. For example, leading players are focusing on improving gabapentinoids, SNRIs, and topical agents while also advancing neuromodulation technologies. Between 2025 and 2026, companies are prioritizing combination therapies and targeted treatments to improve efficacy and patient outcomes.
Generic Competition and Regulatory Challenges Limiting Growth
Despite steady growth, the market faces challenges due to high generic drug penetration and regulatory constraints. Many first-line neuropathic pain drugs, such as gabapentin and pregabalin, have lost patent protection, leading to intense price competition.
According to the U.S. Food and Drug Administration (FDA), over 90% of prescriptions in the U.S. are filled with generic drugs, significantly impacting revenue growth for branded therapies. Additionally, strict regulations around opioid usage due to addiction risks have limited their adoption, particularly in North America and Europe. Supply chain disruptions and pricing pressures in emerging markets further constrain profitability. To address these challenges, companies are focusing on premium therapies such as neuromodulation devices and novel biologics, which offer higher margins and differentiated value propositions.
Market Segmentation
- Based on the drug class, the market is segmented into antidepressants, anticonvulsants, opioids, topical agents, and others.
- Based on the treatment type, the market is segmented into pharmacological treatment and non-pharmacological treatment.
- Based on the indication, the market is segmented into diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, spinal cord injury pain, and others.
Anticonvulsants Segment Leads the Market
The anticonvulsants segment dominates the neuropathic pain treatment market share, primarily due to the widespread use of gabapentin and pregabalin as first-line therapies. These drugs are highly effective in managing neuropathic pain conditions, including diabetic neuropathy and postherpetic neuralgia.
The segment benefits from strong adoption across hospitals and outpatient settings, supported by clinical guidelines recommending anticonvulsants as a primary treatment option. Between 2022 and 2026, pharmaceutical companies have focused on expanding the availability of generic formulations and improving affordability and accessibility. Additionally, increasing patient awareness and early diagnosis have contributed to higher prescription volumes, further strengthening the segment’s dominance.
Neuromodulation Therapies Segment to Record Strong Growth
The neuromodulation therapies segment is expected to witness the fastest growth during the forecast period. This growth is driven by advancements in spinal cord stimulation (SCS) devices and increasing preference for non-opioid pain management solutions. Technological innovations such as high-frequency stimulation and minimally invasive implantation techniques are enhancing treatment outcomes. According to the U.S. FDA, approvals for neuromodulation devices have increased significantly over the past decade, reflecting growing adoption. Investment in research and development by leading companies is further accelerating innovation in this segment. As healthcare systems shift toward non-pharmacological treatments, neuromodulation is expected to gain substantial traction globally.
Regional Outlook
The global neuropathic pain treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the global market due to its advanced healthcare infrastructure and high prevalence of chronic diseases. According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans have diabetes, significantly driving demand for neuropathic pain treatments. Additionally, strong regulatory support from the U.S. FDA for innovative therapies and widespread insurance coverage contribute to market growth. The presence of major pharmaceutical companies further strengthens the country’s leadership position.
China to Record Strong Growth
China is expected to witness rapid growth due to expanding healthcare access and increasing chronic disease burden. According to the International Diabetes Federation (IDF), China accounts for a significant share of global diabetes cases, boosting demand for neuropathic pain treatments. Government initiatives to improve healthcare infrastructure and rising investments in pharmaceutical manufacturing are supporting market expansion. Additionally, growing adoption of advanced therapies and increasing healthcare expenditure are driving growth in the region.
Market Player Outlook
The neuropathic pain treatment market is highly competitive, characterized by the presence of both global pharmaceutical giants and regional generic manufacturers. Companies are focusing on product innovation, cost optimization, and strategic collaborations to strengthen their market position. The key players, such as Pfizer Inc., Johnson & Johnson (Janssen Pharmaceuticals), Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan), and Eli Lilly and Company, dominate the market due to their strong product portfolios and global distribution networks. These companies are investing in research and development, new drug formulations, and neuromodulation technologies to maintain a competitive edge.
Recent Developments
- In July 2025, Johnson & Johnson strengthened its position in the neuropathic and chronic pain treatment landscape through a strategic co-promotion agreement with Pacira BioSciences to expand access to non-opioid pain therapies. The inclusion of ZILRETTA®, an extended-release injectable, enhances early intervention strategies by offering long-lasting pain relief and reducing reliance on surgical or opioid-based treatments.
- In May 2025, Eli Lilly and Company strengthened its position in the Neuropathic Pain Treatment Market through the acquisition of SiteOne Therapeutics, enhancing its pipeline of non-opioid pain therapies. The deal includes STC-004, a Phase 2-ready Nav1.8 inhibitor with potential as a next-generation treatment for chronic and neuropathic pain.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global neuropathic pain treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Neuropathic Pain Treatment Market Sales Analysis – Drug Class | Treatment Type | Indication | Region ($ Million)
- Neuropathic Pain Treatment Market Size, Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Neuropathic Pain Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Neuropathic Pain Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Neuropathic Pain Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Neuropathic Pain Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Neuropathic Pain Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Neuropathic Pain Treatment Market Size, Market Revenue, and Share by Manufacturers
- Neuropathic Pain Treatment Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Pfizer Inc.
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Johnson & Johnson (Janssen Pharmaceuticals)
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Teva Pharmaceutical Industries Ltd.
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Viatris Inc. (Mylan)
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Eli Lilly and Company
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Neuropathic Pain Treatment Market Sales Analysis by Drug Class ($ Million)
5.1 Antidepressants
5.2 Anticonvulsants
5.3 Opioids
5.4 Topical Agents
5.5 Others
- Global Neuropathic Pain Treatment Market Sales Analysis by Treatment Type ($ Million)
6.1 Pharmacological Treatment
6.2 Non-Pharmacological Treatment
- Global Neuropathic Pain Treatment Market Sales Analysis by Indication ($ Million)
7.1 Diabetic Peripheral Neuropathy
7.2 Postherpetic Neuralgia
7.3 Chemotherapy-Induced Peripheral Neuropathy
7.4 Trigeminal Neuralgia
7.5 Spinal Cord Injury Pain
7.6 Others
- Regional Analysis
8.1 North American Neuropathic Pain Treatment Market Sales Analysis – Drug Class | Treatment Type | Indication | Region | Country ($ Million)
8.1.1 United States
8.1.2 Canada
8.2 European Neuropathic Pain Treatment Market Sales Analysis – Drug Class | Treatment Type | Indication | Region | Country ($ Million)
8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Russia
8.2.7 Rest of Europe
8.3 Asia-Pacific Neuropathic Pain Treatment Market Sales Analysis – Drug Class | Treatment Type | Indication | Region | Country ($ Million)
8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific
8.4 Rest of the World Neuropathic Pain Treatment Market Sales Analysis – Drug Class | Treatment Type | Indication | Region | Country ($ Million)
8.4.1 Latin America
8.4.2 Middle East and Africa
- Company Profiles
9.1 AbbVie Inc.
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.2 Amgen Inc.
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.3 AstraZeneca plc
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.4 Aurobindo Pharma Ltd.
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.5 Boston Scientific Corporation
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.6 Bristol Myers Squibb
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.7 Cipla Limited
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.8 Dr. Reddy’s Laboratories Ltd.
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.9 GlaxoSmithKline plc (GSK)
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.10 Grünenthal GmbH
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.11 Hikma Pharmaceuticals PLC
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.12 Lupin Limited
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.13 Mallinckrodt Pharmaceuticals
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies
9.14 Medtronic plc
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies
9.15 Merck & Co., Inc.
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies
9.16 Nevro Corp.
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies
9.17 Novartis AG
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies
9.18 Sanofi S.A.
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies
9.19 Sun Pharmaceutical Industries Ltd.
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies
1. Global Neuropathic Pain Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global Antidepressants Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Anticonvulsants Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Opioids Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Topical Agents Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Others Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Neuropathic Pain Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
8. Global Pharmacological Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Non-Pharmacological Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Neuropathic Pain Treatment Market Research and Analysis by Indication, 2025–2035 ($ Million)
11. Global Diabetic Peripheral Neuropathy Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Postherpetic Neuralgia Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Chemotherapy-Induced Peripheral Neuropathy Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Trigeminal Neuralgia Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Spinal Cord Injury Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Others Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
18. North America Neuropathic Pain Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
19. North America Neuropathic Pain Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
20. North America Neuropathic Pain Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
21. North America Neuropathic Pain Treatment Market Research and Analysis by Indication, 2025–2035 ($ Million)
22. North America Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
23. Europe Neuropathic Pain Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
24. Europe Neuropathic Pain Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
25. Europe Neuropathic Pain Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
26. Europe Neuropathic Pain Treatment Market Research and Analysis by Indication, 2025–2035 ($ Million)
27. Europe Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
28. Asia-Pacific Neuropathic Pain Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
29. Asia-Pacific Neuropathic Pain Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
30. Asia-Pacific Neuropathic Pain Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
31. Asia-Pacific Neuropathic Pain Treatment Market Research and Analysis by Indication, 2025–2035 ($ Million)
32. Asia-Pacific Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
33. Rest of the World Neuropathic Pain Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
34. Rest of the World Neuropathic Pain Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
35. Rest of the World Neuropathic Pain Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
36. Rest of the World Neuropathic Pain Treatment Market Research and Analysis by Indication, 2025–2035 ($ Million)
1. Global Neuropathic Pain Treatment Market Share by Drug Class, 2025 vs 2035 (%)
2. Global Antidepressants Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. Global Anticonvulsants Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. Global Opioids Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 vs 2035 (%)
5. Global Topical Agents Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. Global Others Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
7. Global Neuropathic Pain Treatment Market Share by Treatment Type, 2025 Vs 2035 (%)
8. Global Pharmacological Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
9. Global Non-Pharmacological Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
10. Global Neuropathic Pain Treatment Market Share by Indication, 2025 Vs 2035 (%)
11. Global Diabetic Peripheral Neuropathy Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
12. Global Postherpetic Neuralgia Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 vs 2035 (%)
13. Global Chemotherapy-Induced Peripheral Neuropathy Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
14. Global Trigeminal Neuralgia Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 vs 2035 (%)
15. Global Spinal Cord Injury Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
16. Global Others Neuropathic Pain Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
17. Global Neuropathic Pain Treatment Market Size by Region, 2025 Vs 2035 (%)
18. United States Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
19. Canada Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
20. UK Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
21. France Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
22. Germany Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
23. Italy Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
24. Spain Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
25. Russia Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
26. India Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
27. China Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
28. Japan Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
29. South Korea Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
30. Australia & New Zealand Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
31. ASEAN Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
32. Rest of Asia-Pacific Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
33. Latin America Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
34. Middle East & Africa Neuropathic Pain Treatment Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
